Impact BioMedical Net Income
| IBO Stock | USD 0.48 0.02 4.35% |
As of the 12th of February 2026, Impact BioMedical retains the Market Risk Adjusted Performance of 0.2439, risk adjusted performance of 0.0177, and Downside Deviation of 5.38. Impact BioMedical technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Impact BioMedical Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 2.8 K | Revenue | Earnings Share (4.14) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -32 M | -30.4 M | |
| Net Loss | -22.3 M | -21.2 M | |
| Net Loss | -22.2 M | -21.1 M | |
| Net Loss | (0.04) | (0.05) |
Impact | Net Income | Build AI portfolio with Impact Stock |
Evaluating Impact BioMedical's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Impact BioMedical's fundamental strength.
Latest Impact BioMedical's Net Income Growth Pattern
Below is the plot of the Net Income of Impact BioMedical over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Impact BioMedical financial statement analysis. It represents the amount of money remaining after all of Impact BioMedical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Impact BioMedical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Impact BioMedical's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (35.53 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Impact Net Income Regression Statistics
| Arithmetic Mean | (1,517,974) | |
| Coefficient Of Variation | (125.37) | |
| Mean Deviation | 1,409,781 | |
| Median | (408,289) | |
| Standard Deviation | 1,903,071 | |
| Sample Variance | 3.6T | |
| Range | 7M | |
| R-Value | (0.58) | |
| Mean Square Error | 2.6T | |
| R-Squared | 0.34 | |
| Significance | 0.01 | |
| Slope | (219,711) | |
| Total Sum of Squares | 57.9T |
Impact Net Income History
Other Fundumenentals of Impact BioMedical
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Impact Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Impact BioMedical is extremely important. It helps to project a fair market value of Impact Stock properly, considering its historical fundamentals such as Net Income. Since Impact BioMedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Impact BioMedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Impact BioMedical's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Impact diversify its offerings? Factors like these will boost the valuation of Impact BioMedical. Market participants price Impact higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Impact BioMedical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Impact BioMedical's market price often diverges from its book value, the accounting figure shown on Impact's balance sheet. Smart investors calculate Impact BioMedical's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Impact BioMedical's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Impact BioMedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Impact BioMedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Impact BioMedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Impact BioMedical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Impact BioMedical's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Impact BioMedical.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Impact BioMedical on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Impact BioMedical or generate 0.0% return on investment in Impact BioMedical over 90 days. Impact BioMedical is related to or competes with Neurosense Therapeutics, AIM ImmunoTech, Brainstorm Cell, Alaunos Therapeutics, Moolec Science, Cyclerion Therapeutics, and Quoin Pharmaceuticals. Impact BioMedical is entity of United States More
Impact BioMedical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Impact BioMedical's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Impact BioMedical upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.38 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 61.57 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 8.0 |
Impact BioMedical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Impact BioMedical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Impact BioMedical's standard deviation. In reality, there are many statistical measures that can use Impact BioMedical historical prices to predict the future Impact BioMedical's volatility.| Risk Adjusted Performance | 0.0177 | |||
| Jensen Alpha | 0.043 | |||
| Total Risk Alpha | (0.80) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.2339 |
Impact BioMedical February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0177 | |||
| Market Risk Adjusted Performance | 0.2439 | |||
| Mean Deviation | 4.1 | |||
| Semi Deviation | 4.38 | |||
| Downside Deviation | 5.38 | |||
| Coefficient Of Variation | 9075.27 | |||
| Standard Deviation | 7.41 | |||
| Variance | 54.91 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.043 | |||
| Total Risk Alpha | (0.80) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.2339 | |||
| Maximum Drawdown | 61.57 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 8.0 | |||
| Downside Variance | 28.94 | |||
| Semi Variance | 19.21 | |||
| Expected Short fall | (5.96) | |||
| Skewness | 4.08 | |||
| Kurtosis | 26.17 |
Impact BioMedical Backtested Returns
Impact BioMedical appears to be out of control, given 3 months investment horizon. Impact BioMedical holds Efficiency (Sharpe) Ratio of 0.0322, which attests that the entity had a 0.0322 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Impact BioMedical, which you can use to evaluate the volatility of the firm. Please utilize Impact BioMedical's Market Risk Adjusted Performance of 0.2439, risk adjusted performance of 0.0177, and Downside Deviation of 5.38 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Impact BioMedical holds a performance score of 2. The company retains a Market Volatility (i.e., Beta) of 0.31, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Impact BioMedical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Impact BioMedical is expected to be smaller as well. Please check Impact BioMedical's treynor ratio and the relationship between the downside variance and day median price , to make a quick decision on whether Impact BioMedical's current trending patterns will revert.
Auto-correlation | -0.11 |
Insignificant reverse predictability
Impact BioMedical has insignificant reverse predictability. Overlapping area represents the amount of predictability between Impact BioMedical time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Impact BioMedical price movement. The serial correlation of -0.11 indicates that less than 11.0% of current Impact BioMedical price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.11 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Impact BioMedical reported net income of (35.53 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
Impact Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Impact BioMedical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Impact BioMedical could also be used in its relative valuation, which is a method of valuing Impact BioMedical by comparing valuation metrics of similar companies.Impact BioMedical is currently under evaluation in net income category among its peers.
Impact Fundamentals
| Return On Equity | -3.47 | ||||
| Return On Asset | -0.0768 | ||||
| Operating Margin | (52.67) % | ||||
| Current Valuation | 73.15 M | ||||
| Shares Outstanding | 104.62 M | ||||
| Shares Owned By Insiders | 89.30 % | ||||
| Shares Owned By Institutions | 1.20 % | ||||
| Number Of Shares Shorted | 239 K | ||||
| Price To Book | 1.24 X | ||||
| Price To Sales | 2,009 X | ||||
| Revenue | 2.33 M | ||||
| Gross Profit | 23 K | ||||
| EBITDA | (1.54 M) | ||||
| Net Income | (35.53 M) | ||||
| Cash And Equivalents | 2 M | ||||
| Total Debt | 8.88 M | ||||
| Book Value Per Share | (0.97) X | ||||
| Cash Flow From Operations | (5.64 M) | ||||
| Short Ratio | 4.15 X | ||||
| Earnings Per Share | (4.14) X | ||||
| Market Capitalization | 50.22 M | ||||
| Total Asset | 20.29 M | ||||
| Retained Earnings | (37.67 M) | ||||
| Working Capital | (7.34 M) | ||||
| Net Asset | 20.29 M |
About Impact BioMedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Impact BioMedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Impact BioMedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Impact BioMedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Impact BioMedical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Impact BioMedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Impact BioMedical will appreciate offsetting losses from the drop in the long position's value.Moving against Impact Stock
The ability to find closely correlated positions to Impact BioMedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Impact BioMedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Impact BioMedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Impact BioMedical to buy it.
The correlation of Impact BioMedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Impact BioMedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Impact BioMedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Impact BioMedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Impact Stock, please use our How to Invest in Impact BioMedical guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Will Biotechnology sector continue expanding? Could Impact diversify its offerings? Factors like these will boost the valuation of Impact BioMedical. Market participants price Impact higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Impact BioMedical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Impact BioMedical's market price often diverges from its book value, the accounting figure shown on Impact's balance sheet. Smart investors calculate Impact BioMedical's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Impact BioMedical's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Impact BioMedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Impact BioMedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Impact BioMedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.